Impact of the Novel CoronaviruS (COVID-19) on Frontline PharmacIsts Roles and ServicEs: INSPIRE Worldwide Survey
Abstract
:1. Introduction
2. Methods
2.1. Study Design
2.2. Participants
2.3. Participant Recruitment
2.4. Data Collection Instrument
2.5. Data Analysis
3. Results
3.1. Pharmacists’ Roles and Services
3.2. Challenges
3.3. Engaged with Disaster Response
4. Discussion
5. Limitations
6. Conclusions
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Information Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Cadogan, C.A.; Hughes, C.M. On the frontline against COVID-19: Community pharmacists’ contribution during a public health crisis. Res. Soc. Adm. Pharm. 2021, 17, 2032–2035. [Google Scholar] [CrossRef]
- International Pharmaceutical Federation. FIP Health Advisory COVID-19: Guidelines for Pharmacists and the Pharmacy Workforce [Internet]. Available online: https://www.fip.org/file/4729 (accessed on 18 August 2022).
- Visacri, M.B.; Figueiredo, I.V.; Lima, T.d.M. Role of pharmacist during the COVID-19 pandemic: A scoping review. Res. Soc. Adm. Pharm. 2021, 17, 1799–1806. [Google Scholar] [CrossRef] [PubMed]
- Watson, K.E.; Schindel, T.J.; Barsoum, M.E.; Kung, J.Y. COVID the catalyst for evolving professional role identity? A scoping review of global pharmacists’ roles and services as a response to the COVID-19 pandemic. Pharmacy 2021, 9, 99. [Google Scholar] [CrossRef] [PubMed]
- Bragazzi, N.L.; Mansour, M.; Bonsignore, A.; Ciliberti, R. The Role of Hospital and Community Pharmacists in the Management of COVID-19: Towards an Expanded Definition of the Roles, Responsibilities, and Duties of the Pharmacist. Pharmacy 2020, 8, 140. [Google Scholar] [CrossRef] [PubMed]
- Bukhari, N.; Rasheed, H.; Nayyer, B.; Babar, Z.-U.-D. Pharmacists at the frontline beating the COVID-19 pandemic. J. Pharm. Policy Pract. 2020, 13, 8. [Google Scholar] [CrossRef] [Green Version]
- Goff, D.A.; Ashiru-Oredope, D.; Cairns, K.A.; Eljaaly, K.; Gauthier, T.P.; Langford, B.J.; Mahmoud, S.F.; Messina, A.P.; Michael, U.C.; Saad, T.; et al. Global contributions of pharmacists during the COVID-19 pandemic. J. Am. Coll. Clin. Pharm. 2020, 3, 1480–1492. [Google Scholar] [CrossRef]
- Merks, P.; Jakubowska, M.; Drelich, E.; Świeczkowski, D.; Bogusz, J.; Bilmin, K.; Sola, K.F.; May, A.; Majchrowska, A.; Koziol, M.; et al. The legal extension of the role of pharmacists in light of the COVID-19 global pandemic. Res. Soc. Adm. Pharm. 2021, 17, 1807–1812. [Google Scholar] [CrossRef]
- Kasahun, G.G.; Kahsay, G.M.; Asayehegn, A.T.; Demoz, G.T.; Desta, D.M.; Gebretekle, G.B. Pharmacy preparedness and response for the prevention and control of coronavirus disease (COVID-19) in Aksum, Ethiopia; a qualitative exploration. BMC Health Serv. Res. 2020, 20, 913. [Google Scholar] [CrossRef]
- Kristina, S.A.; Herliana, N.; Hanifah, S. The perception of role and responsibilities during covid-19 pandemic: A survey from indonesian pharmacists. Int. J. Pharm. Res. 2020, 12, 3034–3039. [Google Scholar] [CrossRef]
- Ou, H.T.; Yang, Y.H.K. Community Pharmacists in Taiwan at the Frontline Against the Novel Coronavirus Pandemic: Gatekeepers for the Rationing of Personal Protective Equipment. Ann. Intern. Med. 2020, 173, 149–150. [Google Scholar] [CrossRef] [Green Version]
- Watson, K.E.; Schindel, T.J.; Chan, J.C.H.; Tsuyuki, R.T.; Al Hamarneh, Y.N. A photovoice study on community pharmacists’ roles and lived experiences during the COVID-19 pandemic. Res. Soc. Adm. Pharm. 2023, in press. [Google Scholar] [CrossRef] [PubMed]
- Zheng, S.-Q.; Yang, L.; Zhou, P.-X.; Li, H.-B.; Liu, F.; Zhao, R.-S. Recommendations and guidance for providing pharmaceutical care services during COVID-19 pandemic: A China perspective. Res. Soc. Adm. Pharm. 2021, 17, 1819–1824. [Google Scholar] [CrossRef] [PubMed]
- Mullen, E.; Smith, G.H.; Irwin, A.N.; Angeles, M. Pandemic H1n1 influenza virus: Academy perspectives on pharmacy’s critical role in treatment, prevention. J. Am. Pharm. Assoc. 2009, 49, 728. [Google Scholar] [CrossRef] [PubMed]
- Miller, S.; Patel, N.; Vadala, T.; Abrons, J.; Cerulli, J. Defining the pharmacist role in the pandemic outbreak of novel H1N1 influenza. J. Am. Pharm. Assoc. 2012, 52, 763–767. [Google Scholar] [CrossRef] [PubMed]
- Sokolow, L.Z.; Patel, A.; Koonin, L.M.; Graitcer, S.B. Scripted Surge Pharmacy Pandemic Exercise: Testing Vaccine Administration and Antiviral Dispensing. Health Secur. 2018, 16, 262–273. [Google Scholar] [CrossRef]
- Rubin, S.; Schulman, R.; Roszak, A.; Herrmann, J.; Patel, A.; Koonin, L. Leveraging Partnerships Among Community Pharmacists, Pharmacies, and Health Departments to Improve Pandemic Influenza Response. Biosecur. Bioterror. 2014, 12, 76–84. [Google Scholar] [CrossRef]
- Watson, K.E.; Singleton, J.A.; Tippett, V.; Nissen, L.M. Defining pharmacists’ roles in disasters: A delphi study. PLoS ONE 2019, 14, e0227132. [Google Scholar] [CrossRef] [Green Version]
- Lee, D.H.; Watson, K.E.; Al Hamarneh, Y.N. Impact of COVID-19 on frontline pharmacists’ roles and services in Canada: The INSPIRE Survey. Can. Pharm. J. 2021, 154, 368–373. [Google Scholar] [CrossRef]
- Vandenbroucke, J.P.; von Elm, E.; Altman, D.G.; Gøtzsche, P.C.; Mulrow, C.D.; Pocock, S.J.; Poole, C.; Schlesselman, J.J.; Egger, M. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): Explanation and elaboration. PLoS Med. 2007, 4, e297. [Google Scholar] [CrossRef] [Green Version]
- Lee, L.; Peterson, G.M.; Naunton, M.; Jackson, S.; Bushell, M. Protecting the Herd: Why Pharmacists Matter in Mass Vaccination. Pharmacy 2020, 8, 199. [Google Scholar] [CrossRef]
- Alberta College of Pharmacy. Pharmacists Needed to Administer COVID-19 Vaccine [Internet]. Available online: https://abpharmacy.ca/articles/pharmacists-needed-administer-covid-19-vaccine (accessed on 5 February 2022).
- Anonymous. ASHP principles for COVID-19 vaccine distribution, allocation, and mass immunization. Am. J. Health-Syst. Pharm. 2020, 77, 2112–2113. [Google Scholar] [CrossRef]
- Mohamed Ibrahim, O.; Ibrahim, R.M.; Ibrahim, Y.A.; Madawi, E.A.; Al Deri, M.Y. Shedding the light on Pharmacists’ roles during COVID-19 global pandemic. Saudi Pharm. J. 2022, 30, 14–27. [Google Scholar] [CrossRef] [PubMed]
- Bhat, S.; Kehasse, A. Additional clinical pharmacists roles during COVID-19. J. Am. Coll. Clin. Pharm. 2020, 3, 825. [Google Scholar] [CrossRef]
- Moosavi, J.; Fathollahi-Fard, A.M.; Dulebenets, M.A. Supply chain disruption during the COVID-19 pandemic: Recognizing potential disruption management strategies. Int. J. Disaster Risk Reduct. 2022, 75, 102983. [Google Scholar] [CrossRef] [PubMed]
- Johnston, K.; O’Reilly, C.L.; Scholz, B.; Mitchell, I. The experiences of pharmacists during the global COVID-19 pandemic: A thematic analysis using the jobs demands-resources framework. Res. Soc. Adm. Pharm. 2022, 18, 3649–3655. [Google Scholar] [CrossRef] [PubMed]
- Demerouti, E.; Bakker, A.B.; Nachreiner, F.; Schaufeli, W.B. The job demands-resources model of burnout. J. Appl. Psychol. 2001, 86, 499–512. [Google Scholar] [CrossRef]
- Johnston, K.; O’Reilly, C.L.; Scholz, B.; Georgousopoulou, E.N.; Mitchell, I. Burnout and the challenges facing pharmacists during COVID-19: Results of a national survey. Int. J. Clin. Pharm. 2021, 43, 716–725. [Google Scholar] [CrossRef]
- International Pharmaceutical Federation (FIP). FIP Statement of Professional Standards the Role of the Pharmacist in Crisis Management: Including Manmade and Natural Disasters and Pandemics; International Pharmaceutical Federation: The Hague, The Netherlands, 2006. [Google Scholar]
- International Pharmaceutical Federation (FIP). Responding to Disasters: Guidelines for Pharmacy 2016; International Pharmaceutical Federation: The Hague, The Netherlands, 2016. [Google Scholar]
Number of Participants (n = 505) | Percentage (%) | |
---|---|---|
Practice Setting | ||
Community Pharmacy (e.g., independent, chain, franchise) | 291 | 57.6 |
Team-based Community Practice (e.g., primary care network, family health team) | 25 | 5.0 |
Acute Care/Inpatient Care (e.g., hospital) | 125 | 24.8 |
Ambulatory/Outpatient Clinic (e.g., specialty clinics) | 44 | 8.7 |
Continuing or long-Term Care | 10 | 2.0 |
Worked across multiple different practice settings | 87 | 17.2 |
Other (e.g., academia, government, research, industry, etc.) | 20 | 4.0 |
WHO Region * | ||
African Region | 2 | 0.4 |
Eastern Mediterranean Region | 79 | 15.6 |
European Region | 12 | 2.4 |
Region of the Americas | 357 | 70.7 |
Western Pacific Region | 41 | 8.1 |
Undisclosed | 14 | 2.8 |
Yes | No | Role not Relevant to Participant’s Practice Setting | Role not Relevant to Participant’s Country | |
---|---|---|---|---|
Responding to drug information requests (n = 501) | 448 (89.4%) | 33 (6.6%) | 20 (4.0%) | 0 |
Allaying patients fears and anxiety about COVID-19 (n = 499) | 413 (82.8%) | 64 (12.8%) | 20 (4.0%) | 2 (0.4%) |
Educating the public on reducing the spread of COVID-19 (e.g., handwashing, physical/social-distancing) (n = 503) | 409 (81.3%) | 66 (13.1%) | 27 (5.4%) | 1 (0.2%) |
Addressing misinformation on COVID-19 treatments and vaccination to patients (n = 502) | 397 (79.1%) | 74 (14.7%) | 30 (6.0%) | 1 (0.2%) |
Performing medication reviews (n = 498) | 391 (78.5%) | 74 (14.9%) | 32 (6.4%) | 1 (0.2%) |
Managing and/or monitoring patients’ chronic diseases (n = 501) | 362 (72.3%) | 81 (16.2%) | 58 (11.6%) | 0 |
Rationing medicine supplies (n = 501) | 341 (68.1%) | 107 (21.4%) | 51 (10.2%) | 2 (0.4%) |
Treating ambulatory conditions (e.g., mild constipation, mild pain) (n = 501) | 330 (65.9%) | 92 (18.4%) | 78 (15.6%) | 1 (0.2%) |
Renewing/Extending prescriptions (n = 502) | 293 (58.4%) | 108 (21.5%) | 93 (18.5%) | 8 (1.6%) |
Administering influenza and other vaccines (n = 502) | 278 (55.4%) | 143 (28.5%) | 68 (13.6%) | 13 (2.6%) |
Delivering medications to patients at home (n = 501) | 272 (54.3%) | 128 (25.6%) | 97 (19.4%) | 4 (0.8%) |
Providing PPE supplies to patients (e.g., face masks) (n = 500) | 258 (51.6%) | 192 (38.4%) | 49 (9.8%) | 1 (0.2%) |
Prescribing emergency supply refills (n = 501) | 255 (50.9%) | 130 (26.0%) | 110 (22.0%) | 6 (1.2%) |
Administering the COVID-19 vaccine (n = 501) | 225 (44.9%) | 197 (39.3%) | 66 (13.2%) | 13 (2.6%) |
Providing telehealth or tele-pharmacy consults (n = 501) | 226 (45.1%) | 201 (40.1%) | 66 (13.2%) | 8 (1.6%) |
Addressing misinformation on COVID-19 treatments and vaccination to other healthcare providers (n = 503) | 224 (44.5%) | 207 (41.2%) | 69 (13.7) | 3 (0.6%) |
Guiding policy development on COVID-19 (n = 500) | 139 (27.8%) | 284 (56.8%) | 73 (14.6%) | 4 (0.8%) |
Advocating for COVID-19 public health messaging (e.g., radio, television, community outreach) (n = 499) | 127 (25.5%) | 290 (58.1%) | 79 (15.8%) | 3 (0.6%) |
Participating on COVID-19 taskforce (n = 498) | 127 (25.5%) | 299 (60.0%) | 69 (13.9%) | 3 (0.6%) |
Providing drive-thru pharmacy services (e.g., anticoagulant clinic, INR testing, medication dispensing, COVID-19 testing) (n = 499) | 122 (24.5%) | 259 (51.9%) | 107 (21.4%) | 11 (2.2%) |
Providing Psychological First Aid (e.g., identifying patients at risk of mental health crises) (n = 500) | 106 (21.2%) | 315 (63.0%) | 72 (14.4%) | 7 (11.4%) |
Compounding hand sanitizers (n = 500) | 84 (16.8%) | 318 (63.6%) | 93 (18.6%) | 5 (1.0%) |
Contributing to/establishing a field hospital for COVID-19 (n = 499) | 55 (11.0%) | 320 (64.1%) | 117 (23.5%) | 7 (23.5%) |
Coordinating clinical trial management specific to COVID-19 treatments (n = 499) | 51 (10.2%) | 334 (66.9%) | 107 (21.4%) | 7(1.4%) |
Reporting domestic violence (n = 499) | 43 (8.6%) | 378 (75.8%) | 72 (14.4%) | 6 (1.2%) |
Working in a field hospital for COVID-19 (n = 500) | 28 (5.6%) | 345 (69.0%) | 119 (23.8%) | 8 (1.6%) |
Eastern Mediterranean Region (n = 79) | European Region (n = 12) | Region of the Americas (n = 357) | Western Pacific Region (n = 41) | African Region (n = 2) | Undisclosed Location (n = 14) | Total (n = 505) | |
---|---|---|---|---|---|---|---|
Increased stress level | 46 (58.2) | 10 (83.3) | 319 (89.4) | 34 (82.9) | 0 | 6 (42.9) | 415 (82.2) |
Decreased supply of medications | 30 (38.0) | 8 (66.7) | 279 (78.2) | 36 (87.8) | 2 (100) | 5 (35.7) | 360 (71.3) |
Correcting misinformation with patients | 26 (32.9) | 8 (66.7) | 258 (72.3) | 26 (63.4) | 1 (50) | 6 (42.9) | 325 (64.4) |
Inadequate staffing | 31 (39.2) | 4 (33.3) | 257 (72.0) | 25 (61.0) | 2 (100) | 3 (21.4) | 322 (63.8) |
General supply shortage | 25 (31.7) | 7 (58.3) | 244 (68.4) | 36 (87.8) | 2 (100) | 7 (50.0) | 321 (63.6) |
Concern for safety | 27 (34.2) | 6 (50.0) | 245 (68.6) | 31 (75.6) | 1 (50) | 5 (35.7) | 315 (62.4) |
Lack of personal-protective equipment | 39 (49.4) | 7 (58.3) | 201 (56.3) | 28 (68.3) | 1 (50.0) | 6 (42.9) | 282 (55.8) |
Unfair patient expectations | 28 (35.4) | 7 (58.3) | 202 (56.6) | 24 (58.5) | 0 | 5 (35.7) | 266 (52.7) |
Lack of time for clinical counseling | 30 (38.0) | 6 (50.0) | 199 (55.7) | 18 (43.9) | 1 (50.0) | 4 (28.6) | 258 (51.1) |
HR-related issues | 30 (38.0) | 8 (66.7) | 194 (54.3) | 19 (46.3) | 1 (50.0) | 3 (21.4) | 255 (50.5) |
Inadequate time for breaks/meals | 20 (25.3) | 4 (33.3) | 199 (55.7) | 20 (48.8) | 1 (50.0) | 4 (28.6) | 248 (49.1) |
Prescription surge | 11 (13.9) | 4 (33.3) | 168 (47.1) | 26 (63.4) | 1 (50.0) | 4 (28.6) | 214 (42.4) |
Time required to develop safety plans for COVID-19 | 26 (32.9) | 3 (25.0) | 151 (42.3) | 12 (29.3) | 0 | 2 (14.3) | 194 (38.4) |
Lack of access to COVID-19 vaccines | 15 (19.0) | 1 (8.3) | 162 (45.4) | 6 (14.6) | 0 | 3 (21.4) | 187 (37.0) |
Insurance issues | 19 (24.1) | 1 (8.3) | 141 (39.5) | 5 (12.2) | 0 | 5 (35.7) | 171 (33.9) |
Extra cost associated with following the public health regulations | 16 (20.3) | 3 (25.0) | 120 (33.6) | 22 (53.7) | 0 | 2 (14.3) | 163 (32.3) |
Feeling unsure of pharmacy’s role or responsibilities | 20 (25.3) | 5 (41.7) | 114 (31.9) | 13 (31.7) | 0 | 2 (14.3) | 154 (30.5) |
Loss of business | 15 (19.0) | 4 (33.3) | 87 (24.4) | 17 (41.5) | 1 (50.0) | 2 (14.3) | 126 (25.0) |
Childcare | 16 (20.3) | 1 (8.3) | 95 (26.6) | 10 (24.4) | 0 | 3 (21.4) | 125 (24.8) |
Not feeling confident about delivering expanded scope of practice services during COVID-19 | 9 (11.4) | 2 (16.7) | 82 (23.0) | 5 (12.2) | 0 | 1 (7.1) | 99 (19.6) |
Eastern Mediterranean Region (n = 79) | European Region (n = 12) | Region of the Americas (n = 357) | Western Pacific Region (n = 41) | African Region (n = 2) | Undisclosed Location (n = 14) | Total (n = 505) | |
---|---|---|---|---|---|---|---|
Were you consulted about COVID-19 in terms of pharmacist roles/expectations for pharmacy services? | |||||||
Yes | 44(55.7) | 7(58.3) | 108(30.5) | 13(31.7) | 0 | 7(58.3) | 179(35.8) |
If yes, by whom? | |||||||
Pharmacy organizations | 19 (43.2) | 5 (71.4) | 40 (37.0) | 10 (76.9) | 0 | 2 (28.6) | 77 (43.0) |
Administration teams in hospitals | 6 (13.6) | 3 (42.9) | 54 (50.0) | 3 (23.1) | 3 (42.9) | 67 (37.4) | |
Public health services | 17 (38.6) | 1 (14.3) | 29 (26.9) | 7 (53.9) | 1 (14.3) | 57 (31.8) | |
Government | 12 (27.3) | 1 (14.3) | 24 (22.0) | 5 (38.5) | 3 (42.9) | 44 (24.6) | |
Corporate | 12 (27.3) | 1 (14.3) | 25 (23.2) | 5 (38.5) | 1 (14.3) | 44 (24.6) | |
Local disaster response organizations | 5 (11.4) | 0 (0.0) | 8 (7.4) | 3 (23.1) | 1 (14.3) | 17 (9.5) | |
Other (e.g., university, schools, colleagues) | 2 (4.6) | 1 (14.3) | 6 (5.6) | 0 (0.0) | 0 (0.0) | 9 (5.0) |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Watson, K.E.; Lee, D.H.; Nusair, M.B.; Al Hamarneh, Y.N. Impact of the Novel CoronaviruS (COVID-19) on Frontline PharmacIsts Roles and ServicEs: INSPIRE Worldwide Survey. Pharmacy 2023, 11, 66. https://doi.org/10.3390/pharmacy11020066
Watson KE, Lee DH, Nusair MB, Al Hamarneh YN. Impact of the Novel CoronaviruS (COVID-19) on Frontline PharmacIsts Roles and ServicEs: INSPIRE Worldwide Survey. Pharmacy. 2023; 11(2):66. https://doi.org/10.3390/pharmacy11020066
Chicago/Turabian StyleWatson, Kaitlyn E., Dillon H. Lee, Mohammad B. Nusair, and Yazid N. Al Hamarneh. 2023. "Impact of the Novel CoronaviruS (COVID-19) on Frontline PharmacIsts Roles and ServicEs: INSPIRE Worldwide Survey" Pharmacy 11, no. 2: 66. https://doi.org/10.3390/pharmacy11020066
APA StyleWatson, K. E., Lee, D. H., Nusair, M. B., & Al Hamarneh, Y. N. (2023). Impact of the Novel CoronaviruS (COVID-19) on Frontline PharmacIsts Roles and ServicEs: INSPIRE Worldwide Survey. Pharmacy, 11(2), 66. https://doi.org/10.3390/pharmacy11020066